Investors
Welcome to Mendus’ Investor Relations page. Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.
Board of directors
According to the articles of association the board of directors shall consist of at least three (3) and at most eight (8) board members without deputies. Mendus’ board of directors currently consists of five(5) board members, including the chairman of the board of directors. All board members have been appointed until the end of next annual general meeting.
For information regarding the board’s work and remuneration, please refer to the company’s corporate governance report.
Sven Andreasson
Chairman since 2024
Board Member since 2020
About:
Sven Andreasson (born 1952, Swedish) has broad experience in biotech and pharmaceutical companies. He was CEO of Active Biotech AB 1999-2008, Beta-Cell NV in Belgium 2008-2012 and Isconova AB 2012-2013 where he initiated and completed a sale of the company in 2013 to the American company Novavax. He was appointed as Senior VP Corporate Development and subsequently as Senior Advisor Business & Corporate Development at Novavax, until May 2024. Sven has also held several senior management positions within Pharmacia in Sweden, Germany, Belgium and France. Previous experience from board assignments includes TiGenix NV, Belgium, Cantargia AB and Chairman of Erytech SA, France. Sven holds a MSc in Engineering from the Stockholm School of Economics and participated in MBA programs from IMEDE Lausanne, INSEAD Fontainebleau and Ashridge London.
Ongoing engagements: Board member of Cellastra Inc USA
Independency:Sven Andreasson is independent in relation to the company, its senior executives and major shareholders.
Shares: 0
Hans Preusting
Board Member since 2021
About:
Dr Hans Preusting (born 1962, Dutch) has previously served as the Chief Business Officer and interim Chief Operating Officer of uniQure. Prior to that he was the VP of Process Development and Manufacturing at AMT, the predecessor of uniQure. Hans is currently CEO of Synerkine Pharma and he also works as an independent consultant for several biotech companies and is co-founder of two biotech start-up companies. He holds two patents and has published over 20 scientific articles. His expertise is focused on business development, product development and manufacturing. Hans holds an MSc in Chemistry and a PhD in Biochemistry from the University of Groningen and an MBA from the Rotterdam School of Management.
Ongoing engagements:
CEO of Synerkine Pharma BV and CDO of DegenRx BV
Independency: Hans Preusting is independent in relation to the company, its senior executives, and major shareholders.
Shares: 8,333
Dharminder Chahal
Board Member since 2021
About:
Dharminder Chahal (born 1976, Dutch) is an experienced person in the global life science industry, renowned for his expertise in founding, financing, and guiding successful ventures. As the managing director of Sairopa, owner and managing director of Exponential B.V., and CEO and co-founder of SkylineDx, he plays pivotal roles in shaping the trajectory of various companies.
Chahal’s extensive network and track record of success are evident through his involvement in significant transactions, such as the sale of Crucell, deVGen, and Ablynx. He also oversees major investments in companies like Galapagos, Zealand Pharma, and BioInvent.
In addition to his executive roles, Chahal serves as a board member or advisor for numerous European companies and funds in the life sciences sector. His background in investment banking and asset management, along with his academic credentials in Business Economics and Aerospace Engineering, further underscore his multidisciplinary expertise.
Through his strategic leadership and extensive experience, Dharminder Chahal continues to make significant contributions to the advancement of the life science industry globally.
Dharminder holds a MSc in Business Administration from Erasmus University Rotterdam and MSc (cum laude) in Aerospace Engineering from Delft University of Technology.
Ongoing engagements:
CEO of SkylineDx BV, Ceradis BV, Medis Holding BV, Pancancer T BV, Sensara Group BV and Vitalnext Products BV as well as advisory board member of BioGeneration Ventures II, Spatium Medical Imaging BV, Thuja Capital Fund I and Gilde Healthcare Funds II and III.
Independency: Dharminder Chahal is independent in relation to the company and its senior executives, and dependent in relation to the major shareholders.
Shares: 264,615
Helén Tuvesson
Board Member since 2020
About:
Dr Helén Tuvesson (born 1962, Swedish) has more than 25 years of experience from the pharmaceutical industry in various positions within Pharmacia and Active Biotech, including as Chief Scientific Officer at Active Biotech for 6 years. In this role she was responsible for the operational research activities and the company’s project portfolio in late-stage clinical development in neurodegenerative diseases and cancer indications. Helén is currently the CEO of Active Biotech AB, which role she has had since 2017. Helén holds a MSc and PhD in Cellular and Molecular Biology in Medical Science from Lund University.
Ongoing engagements:
CEO of Active Biotech AB and chairman of the board of Active Security Trading AB and Actinova AB.
Independency:
Helén Tuvesson is independent in relation to the company, its senior executives and major shareholders.
Shares: 3,200
Ted Fjällman
Board Member since 2023
About:
Dr Ted Fjällman (born 1978, Swedish, Swiss & British) has a background in clinical research, strategy consulting and biotech company building. He has served as committee member of the UK BioIndustry Association (BIA) and on the Management Board of the International Bacterial Vaccines Network (BactiVac). He also co-founded Tekiu, an international knowledge transfer broker. Since 2023 he is CEO of Flerie, an investment company listed on the Nasdaq Stockholm since 2024 with biotech investments across Europe, the US and Israel. Prior to his CEO role he was Partner and Venture Partner at Flerie as well as the CEO of one of its portfolio companies Prokarium in London. He is board member of several drug development companies and was the first CEO of NorthX Biologics after Flerie acquired a manufacturing facility from Charles River to set up this CDMO. Ted holds a BSc in Biology, Physics, Science & Technology Management from the University of Waikato, a MSc from the University of Gothenburg, and MSS from the International Space University, and a PhD in Molecular Biology from the University of Guelph.
Ongoing engagements:
CEO of Flerie AB and board member of Geneos Therapeutics, Vitara Biomedical, Prokarium, Synerkine Pharma, Alder Therapeutics, Roseberry, St Andrews Folkestone and Tekiu.
Independency: Ted Fjällman is independent in relation to the Company and its senior executives, and dependent in relation to the major shareholder Flerie Invest AB.
Shares: 0